| HOME >> BIOLOGY >> TECHNOLOGY |
GUANGZHOU, China, Nov. 10 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a leading developer and distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced that it will conduct a conference call at 9:00 a.m. Eastern Time on Thursday, Nov. 13, 2008 to discuss its third quarter 2008 results.
Joining Mr. Senshan Yang, Chairman and Chief Executive Officer of China Medicine Corporation, will be Ms. Huizhen Yu, Chief Financial Officer. The Company plans to make an earnings announcement prior to the call.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888.482.0024. International callers should dial 617.801.9702, Conference Passcode: 501 582 39.
If you are unable to participate in the call at this time, a replay will be available for 14 days starting on Thursday, Nov. 13, at 11:00 a.m. Eastern Time. To access the replay, dial 888-286-8010, international callers dial 617-801-6888, and enter the passcode of 11677443.
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which
discovers, develops, and distributes over 2,200 pharmaceutical products in
China including prescription and over the counter ("OTC") drugs,
traditional Chinese medicine ("TCM") products, herbs and dietary
supplements. The Company distributes the products to wholesale distributors
in 28 provinces, over 300 hospitals, 500 medicine companies, and 1,788 drug
stores throughout China. The Company actively develops a number of
proprietary products for many uses including oncology, high blood pressure
and the removal of toxins from food and animal feeds. For more information
visit the Company's website at
| SOURCE China Medicine Corporation Copyright©2008 PR Newswire. All rights reserved |